Abnormal promoter methylation of multiple tumor suppressor genes in human bronchial epithelial malignant cells

Liu,Chaoyang; Li,Peng; Gao,Dewei; Zhou,Pingkun; Shao,Yun; Zhang,Qi; Li,Wenbing

doi:10.3892/br.2014.268

Abnormal promoter methylation of multiple tumor suppressor genes in human bronchial epithelial malignant cells

Authors:
- Chaoyang Liu
- Peng Li
- Dewei Gao
- Pingkun Zhou
- Yun Shao
- Qi Zhang
- Wenbing Li
View Affiliations

Affiliations: Surgical Intensive Care Unit, Clinical Division of South Building, PLA General Hospital, Beijing 100853, P.R. China, Department of Radiation Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China, Department of Pathology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, P.R. China
Published online on: April 11, 2014 https://doi.org/10.3892/br.2014.268
Pages: 525-528

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carcinoma of the lung is the leading cause of cancer‑related mortality worldwide. In order to understand the pathogenesis of radiation‑induced lung cancer, we adopted a model of transformed human bronchial epithelial cells (BEP2D) induced by α‑particles. Methylation‑specific polymerase chain reaction was performed to detect aberrant promoter methylation of multiple tumor suppressor genes, including p14ARF, p16INK4a, O6‑methylguanine‑DNA methyltransferase, glutathione S‑transferase P1 and death‑associated protein kinase genes in the BEP2D cell line and its malignant transformant, the BERP35T1 cell line. Our results demonstrated the distinctive methylation pattern for these tumor suppressor genes in radiation‑induced malignant cells, as compared to their wild‑type counterparts. Our study revealed epigenetic signatures for the characterization of radiation‑mediated carcinogenesis and it may facilitate early diagnosis of patients at high risk for lung cancer.

View Figures

View References

1	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
2	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
3	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
4	Boehm JS and Hahn WC: Towards systematic functional characterization of cancer genomes. Nat Rev Genet. 12:487–498. 2011. View Article : Google Scholar : PubMed/NCBI
5	Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 21:5427–5440. 2002. View Article : Google Scholar : PubMed/NCBI
6	Lou T, Xiang X and Wu D: Transformation of human bronchial epithelial cells BEP2D induced by ²³⁸Pu α-particles. Chin J Lung Canc. 3:428–431. 2000.(In Chinese).
7	Willey JC, Broussoud A, Sleemi A, et al: Immortalization of normal human bronchial epithelial cells by human papillomaviruses 16 or 18. Cancer Res. 51:5370–5377. 1991.PubMed/NCBI
8	Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
9	Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG: Inactivation of the DNA repair gene O⁶-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793–797. 1999.
10	Wolf P, Hu YC, Doffek K, Sidransky D and Ahrendt SA: O⁶-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res. 61:8113–8117. 2001.
11	Bialik S and Kimchi A: The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem. 75:189–210. 2006. View Article : Google Scholar : PubMed/NCBI
12	Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB and Herman JG: Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58:4515–4518. 1998.PubMed/NCBI
13	Widschwendter M and Jones PA: The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin Cancer Res. 8:17–21. 2002.PubMed/NCBI
14	Hatziapostolou M and Iliopoulos D: Epigenetic aberrations during oncogenesis. Cell Mol Life Sci. 68:1681–1702. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hall EJ and Hei TK: Genomic instability and bystander effects induced by high-LET radiation. Oncogene. 22:7034–7042. 2003. View Article : Google Scholar : PubMed/NCBI
16	Kashiwabara K, Oyama T, Sano T, Fukuda T and Nakajima T: Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer. 79:215–220. 1998. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Xiong Y and Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:725–734. 1998. View Article : Google Scholar : PubMed/NCBI
18	Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:2984–2991. 1998. View Article : Google Scholar : PubMed/NCBI